BME100 s2015:Group12 12pmL1: Difference between revisions
(One intermediate revision by the same user not shown) | |||
Line 73: | Line 73: | ||
*Medical history of selected individuals required. This is to ensure that the research team does not potentially give a harmful or fatal dose of lipopolysacchride, if the case presents itself. | *Medical history of selected individuals required. This is to ensure that the research team does not potentially give a harmful or fatal dose of lipopolysacchride, if the case presents itself. | ||
*Particularly interested in individuals who have active levels of inflammation. The study's data will have more relevance to the goal at hand if inflammation can be monitored more easily. | *Particularly interested in individuals who have active levels of inflammation. The study's data will have more relevance to the goal at hand if inflammation can be monitored more easily. | ||
*Less keen on healthy individuals whose inflammation levels are more passive or even dormant. Data collected would | *Less keen on healthy individuals whose inflammation levels are more passive or even dormant. Data collected would be less accurate if the team works with healthier subjects. These individuals may be placed into the control group to increase data accuracy if necessary. | ||
*Actual process of recruitment is through more emphasis on speaking to them directly in person, telephone calls, pamphlets going through the mail and advertisements for newspapers, magazines and radio stations. Less emphasis on Internet or email advertisements. The targeted demographic is not as likely to use the Internet or email communication as the other methods described. | *Actual process of recruitment is through more emphasis on speaking to them directly in person, telephone calls, pamphlets going through the mail and advertisements for newspapers, magazines and radio stations. Less emphasis on Internet or email advertisements. The targeted demographic is not as likely to use the Internet or email communication as the other methods described. | ||
Line 93: | Line 93: | ||
Possible Controls: | Possible Controls: | ||
*The team will question the subject on why he or she wants to end the experiment, and would try to convince them to see the | *The team will question the subject on why he or she wants to end the experiment, and would try to convince them to see the study through completion. If however the subject is resistant, they will be discharged from the experiment, and random selection will be needed to fill the vacancy. | ||
*It is one of the team’s best interests to ensure the subject’s personal views are not infringed upon for the duration of the experiment. The team will disclose any information the subject requires before entering the laboratory environment. They have the right to opt out of the experiment at any time. | *It is one of the team’s best interests to ensure the subject’s personal views are not infringed upon for the duration of the experiment. The team will disclose any information the subject requires before entering the laboratory environment. They have the right to opt out of the experiment at any time. |
Revision as of 16:11, 25 January 2015
BME 100 Spring 2015 | Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help | |||||
OUR TEAMLAB 1 WRITE-UPWARNING: All material presented here is highly suspectible to change by the write-up's authors. Final draft will be complete by Tuesday, 11:59 P.M. Independent and Dependent VariablesIndependent Variable: Lipopolysacchride (LPS) would be the variable the research team alters, because according to the ELISA data analysis regarding 10 mg LPS, the levels of inflammotin in the blood sample analyzed were affected by an amount of the drug. The team will be able to deduce how inflammotin levels interact with a certain dosage of LPS by manipulating this variable. Dependent Variable: Inflammotin is the protein responsible for inflammation and is the central part of the experiment the team will conduct. This variable will fluctuate based on the dosage of LPS the research team will administrator to the test groups. Experimental DesignGroups The data for 10 mg lipopolysacchride (LPS) will be used as a guide to set up the groups for the experiment, and will thus not have a group dedicated to the dosage level.
Age limit is between 60 to 70 years of age. The research team believes this is the prime demographic of elderly individuals whose personal health is adequate. These individuals are less likely to succumb to biological factors such as cell decay or organ failure, often from 71 years of age and older. Such issues may complicate the experiment.
Total: 50 subjects
Subject Selection
Sources of Error and Bias
|